Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398073 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
A Phase 1 study of Melanoma (Skin) and Intraocular Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00398073: Completed Phase 1 study of Melanoma (Skin) and Intraocular Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00398073 is a Phase 1 study of Melanoma (Skin) and Intraocular Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398073, a Phase 1 study of Melanoma (Skin) and Intraocular Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells. PURPOSE: This randomized clinical trial is studying two different ways of giving vaccine therapy to compare how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.
Primary Outcome
All toxicity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria v3.0.
Conditions Studied
Interventions
- BIOLOGICAL mouse gp100 plasmid DNA vaccine
- DEVICE The Dermal PowderMed® devices
- OTHER intramuscularly (IM injection)
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
What the finished NCT00398073 record still lists
NCT00398073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Melanoma (Skin) appearing as the primary indexed condition, and to 3 interventions - of which mouse gp100 plasmid DNA vaccine is the first listed.
NCT00398073 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00398073 about?
NCT00398073 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma". RATIONALE: Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Giving the vaccine in different ways may make a stronger immune response and kill more tumor cells. PURPOSE: This randomized clinical trial is studying two different ways of giving vaccine th...
What is the current status of trial NCT00398073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2006-10. Estimated completion is 2011-03.
What conditions does trial NCT00398073 study?
This clinical trial studies the following conditions: Melanoma (Skin), Intraocular Melanoma.
What interventions are being tested in trial NCT00398073?
The interventions under investigation include: mouse gp100 plasmid DNA vaccine (BIOLOGICAL), The Dermal PowderMed® devices (DEVICE), intramuscularly (IM injection) (OTHER).
Who is sponsoring clinical trial NCT00398073?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00398073 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00398073's enrollment target sits among peer trials
35 15th of 30 higher than 15 of 30 other Melanoma (Skin) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia